{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T03:27:18Z","timestamp":1747193238040,"version":"3.40.5"},"reference-count":9,"publisher":"S. Karger AG","issue":"2","license":[{"start":{"date-parts":[[2015,7,8]],"date-time":"2015-07-08T00:00:00Z","timestamp":1436313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"},{"start":{"date-parts":[[2015,7,8]],"date-time":"2015-07-08T00:00:00Z","timestamp":1436313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Case Rep Gastroenterol"],"abstract":"<jats:p>Direct-acting antivirals with or without peginterferon \u03b1 (PEG-IFN \u03b1) plus ribavirin are now available for the treatment of hepatitis C virus (HCV) infection. Direct-acting antivirals are potent inhibitors of HCV replication, but some of them occasionally possess serious adverse events. We experienced a 64-year-old female with chronic HCV genotype 1b infection who showed elevated alanine aminotransferase of 528 IU\/l at week 9 after the commencement of treatment of simeprevir with PEG-IFN \u03b1-2a plus ribavirin. However, she achieved sustained virological response at week 24 after the end of treatment. In Japan, we also have to treat elderly patients infected with HCV and\/or advanced hepatic fibrosis. Until an effective interferon-free regimen is established, direct-acting antivirals with PEG-IFN plus ribavirin may still play a role in the treatment for certain patients. To avoid serious results from adverse events, careful attention and follow-up will be needed in the treatment course of simeprevir with PEG-IFN plus ribavirin for chronic HCV infection.<\/jats:p>","DOI":"10.1159\/000437138","type":"journal-article","created":{"date-parts":[[2015,7,7]],"date-time":"2015-07-07T21:01:29Z","timestamp":1436302889000},"page":"215-220","source":"Crossref","is-referenced-by-count":3,"title":["Sustained Virological Response after 8-Week Treatment of Simeprevir with Peginterferon \u03b1-2a plus Ribavirin in a Japanese Female with Hepatitis C Virus Genotype 1b and IL28B Minor Genotype"],"prefix":"10.1159","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3740-5090","authenticated-orcid":false,"given":"Tatsuo","family":"Kanda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reina","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Nakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Haga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akinobu","family":"Tawada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Arai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumio","family":"Imazeki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Yokosuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2015,7,8]]},"reference":[{"doi-asserted-by":"publisher","key":"ref1","DOI":"10.1002\/hep.510260706"},{"doi-asserted-by":"publisher","key":"ref2","DOI":"10.1073\/pnas.87.17.6547"},{"doi-asserted-by":"publisher","key":"ref3","DOI":"10.1155\/2013\/985972"},{"doi-asserted-by":"publisher","key":"ref4","DOI":"10.1371\/journal.pone.0073615"},{"doi-asserted-by":"publisher","key":"ref5","DOI":"10.1007\/s12072-010-9193-3"},{"doi-asserted-by":"publisher","key":"ref6","DOI":"10.1002\/hep.26641"},{"doi-asserted-by":"publisher","key":"ref7","DOI":"10.1007\/s10620-014-3422-x"},{"doi-asserted-by":"publisher","key":"ref8","DOI":"10.1378\/chest.07-3088"},{"doi-asserted-by":"publisher","key":"ref9","DOI":"10.7150\/ijms.6402"}],"container-title":["Case Reports in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/437138","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/437138","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/437138","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T17:37:11Z","timestamp":1745429831000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000437138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,8]]},"references-count":9,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2015,8,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000437138","archive":["Portico"],"relation":{},"ISSN":["1662-0631"],"issn-type":[{"type":"electronic","value":"1662-0631"}],"subject":[],"published":{"date-parts":[[2015,7,8]]}}}